The next step is to apply this methodology in newly diagnosed patients with epilepsy from the BrainDrugs-Epilepsy cohort study [25] and investigate how SV2A-LEV target engagement is associated with LEV treatment efficacy, including seizure freedom and side effects during follow-up. Here, SV2A is linked to epilepsy.